Goldman Sachs’s Corvus Pharmaceuticals CRVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $681K | Sell |
|
|||||
|
2025
Q1 | $1.17M | Sell |
|
|||||
|
2024
Q4 | $3.13M | Buy |
|
|||||
|
2024
Q3 | $1.99M | Buy |
|
|||||
|
2023
Q4 | – | Sell |
|
|||||
|
2023
Q3 | $72K | Sell |
|
|||||
|
2023
Q2 | $216K | Buy |
|
|||||
|
2022
Q4 | – | Sell |
|
|||||
|
2022
Q3 | $14K | Sell |
|
|||||
|
2022
Q2 | $39K | Sell |
|
|||||
|
2022
Q1 | $116K | Sell |
|
|||||
|
2021
Q4 | $255K | Buy |
|
|||||
|
2021
Q3 | $121K | Sell |
|
|||||
|
2021
Q2 | $68K | Sell |
|
|||||
|
2021
Q1 | $95K | Sell |
|
|||||
|
2020
Q4 | $291K | Sell |
|
|||||
|
2020
Q3 | $415K | Sell |
|
|||||
|
2020
Q2 | $311K | Buy |
|
|||||
|
2020
Q1 | $236K | Buy |
|
|||||
|
2019
Q4 | $583K | Buy |
|
|||||
|
2019
Q3 | $180K | Sell |
|
|||||
|
2019
Q2 | $228K | Buy |
|
|||||
|
2019
Q1 | $109K | Sell |
|
|||||
|
2018
Q4 | $144K | Buy |
|
|||||
|
2018
Q3 | $335K | Sell |
|
|||||
|
2018
Q2 | $856K | Buy |
|
|||||
|
2018
Q1 | $406K | Buy |
|
|||||
|
2017
Q4 | $253K | Buy |
|
|||||
|
2017
Q1 | – | Sell |
|
|||||
|
2016
Q4 | $173K | Sell |
|
|||||
|
2016
Q3 | $406K | Buy |
|
|||||
|
2016
Q2 | $157K | Sell |
|
|||||
|
2016
Q1 | $386K | Buy |
|